Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Accounts Payables (2017 - 2025)

Dianthus Therapeutics has reported Accounts Payables over the past 8 years, most recently at $6.7 million for Q3 2025.

  • Quarterly results put Accounts Payables at $6.7 million for Q3 2025, down 11.45% from a year ago — trailing twelve months through Sep 2025 was $6.7 million (down 11.45% YoY), and the annual figure for FY2024 was $4.6 million, up 75.44%.
  • Accounts Payables for Q3 2025 was $6.7 million at Dianthus Therapeutics, up from $5.4 million in the prior quarter.
  • Over the last five years, Accounts Payables for DNTH hit a ceiling of $8.3 million in Q1 2025 and a floor of $813000.0 in Q2 2023.
  • Median Accounts Payables over the past 4 years was $2.6 million (2024), compared with a mean of $3.7 million.
  • Biggest five-year swings in Accounts Payables: plummeted 75.66% in 2023 and later skyrocketed 453.1% in 2024.
  • Dianthus Therapeutics' Accounts Payables stood at $1.2 million in 2022, then skyrocketed by 123.65% to $2.6 million in 2023, then surged by 75.44% to $4.6 million in 2024, then skyrocketed by 46.43% to $6.7 million in 2025.
  • The last three reported values for Accounts Payables were $6.7 million (Q3 2025), $5.4 million (Q2 2025), and $8.3 million (Q1 2025) per Business Quant data.